{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:01:22Z","timestamp":1790312482977,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Auckland","id":[{"id":"https:\/\/ror.org\/03b94tp07","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Use of adjuvant endocrine therapy (ET) for ductal carcinoma in situ (DCIS) varies widely in clinical practice. We investigated oestrogen receptor (ER) testing, the initiation of ET, and the effect of ET on outcomes for DCIS in New Zealand.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Women with DCIS (2000\u20132022) were identified from the New Zealand Breast Cancer Foundation National Register and linked to the national pharmaceutical data. Logistic regression identified factors associated with ER testing, and cumulative incidence of breast cancer events was estimated with death as a competing risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 5813 women with DCIS, 894 patients (15.4%) had ER testing, with the rate increasing from 11.1% in 2000 to 23.3% in 2006, before declining to 13.9% in 2022. The Waikato region contributed 65.6% of ER tests. In Waikato, testing was more likely among women who received adjuvant radiotherapy after breast-conserving surgery, likely reflecting a site-specific clinical practice. In other regions, testing was more frequent among older women, M\u0101ori ethnicity, those with symptomatic presentation, and those with DCIS size\u2009&gt;\u200920\u00a0mm, potentially reflecting selective testing. Among 729 patients with ER-positive DCIS, only 183 (25.1%) commenced ET, of whom 80.3% were in Waikato. ET users had the lowest cumulative risk of breast cancer event, but differences were not statistically significant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ER testing and initiation of ET for DCIS remained low, except in Waikato, where clinical centres participated in ET trials and ER testing became more common. Standardised ER testing and greater clinician participation in clinical trials may lead to improved evidence-based care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10549-026-08072-7","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T06:55:03Z","timestamp":1788332103000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oestrogen receptor testing and initiation of adjuvant endocrine therapy in women with ductal carcinoma in situ: a population-based study"],"prefix":"10.1007","volume":"219","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4409-9516","authenticated-orcid":false,"given":"Qian","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Elwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alana","family":"Cavadino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phyu Sin","family":"Aye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandar","family":"Tin Tin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"8072_CR1","unstructured":"(2017) National Screening Unit, Te Whatu Ora, Wellington. BreastScreen Aotearoa 2017 Monitoring Report"},{"key":"8072_CR2","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1056\/NEJMoa1206809","volume":"367","author":"A Bleyer","year":"2012","unstructured":"Bleyer A, Welch HG (2012) Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med 367:1998\u20132005. https:\/\/doi.org\/10.1056\/NEJMoa1206809","journal-title":"N Engl J Med"},{"key":"8072_CR3","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1158\/1055-9965.EPI-18-1262","volume":"28","author":"MD Ryser","year":"2019","unstructured":"Ryser MD, Hendrix LH, Worni M, Liu Y, Hyslop T, Hwang ES (2019) Incidence of Ductal Carcinoma In Situ in the United States, 2000\u20132014. Cancer Epidemiol Biomarkers Prev 28:1316\u20131323. https:\/\/doi.org\/10.1158\/1055-9965.EPI-18-1262","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"8072_CR4","doi-asserted-by":"publisher","first-page":"m1570","DOI":"10.1136\/bmj.m1570","volume":"369","author":"GS Mannu","year":"2020","unstructured":"Mannu GS, Wang Z, Broggio J, Charman J, Cheung S et al (2020) Invasive breast cancer and breast cancer mortality after ductal carcinoma in situ in women attending for breast screening in England, 1988\u20132014: population based observational cohort study. BMJ 369:m1570. https:\/\/doi.org\/10.1136\/bmj.m1570","journal-title":"BMJ"},{"key":"8072_CR5","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1038\/s41416-020-1023-3","volume":"123","author":"IM Miligy","year":"2020","unstructured":"Miligy IM, Toss MS, Shiino S, Oni G, Syed BM et al (2020) The clinical significance of oestrogen receptor expression in breast ductal carcinoma in situ. Br J Cancer 123:1513\u20131520. https:\/\/doi.org\/10.1038\/s41416-020-1023-3","journal-title":"Br J Cancer"},{"key":"8072_CR6","doi-asserted-by":"publisher","first-page":"104521","DOI":"10.1016\/j.breast.2025.104521","volume":"82","author":"Q Chen","year":"2025","unstructured":"Chen Q, Campbell I, Elwood M, Cavadino A, Aye PS, Tin Tin S (2025) The effects of adjuvant endocrine therapy on long-term outcomes from ductal carcinoma in situ: a systematic review and meta-analysis. Breast 82:104521. https:\/\/doi.org\/10.1016\/j.breast.2025.104521","journal-title":"Breast"},{"key":"8072_CR7","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1200\/JCO.19.02309","volume":"38","author":"KH Allison","year":"2020","unstructured":"Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA et al (2020) Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO\/CAP Guideline Update. J Clin Oncol 38:1346\u20131366. https:\/\/doi.org\/10.1200\/JCO.19.02309","journal-title":"J Clin Oncol"},{"key":"8072_CR8","unstructured":"Network NCC (2023) NCCN clinical practice guidelines in oncology: breast cancer, version 3. National Comprehensive Cancer Network"},{"key":"8072_CR9","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1200\/JCO.2006.10.2699","volume":"25","author":"TW Yen","year":"2007","unstructured":"Yen TW, Kuerer HM, Ottesen RA, Rouse L, Niland JC et al (2007) Impact of randomized clinical trial results in the national comprehensive cancer network on the use of tamoxifen after breast surgery for ductal carcinoma in situ. J Clin Oncol 25:3251\u20133258. https:\/\/doi.org\/10.1200\/JCO.2006.10.2699","journal-title":"J Clin Oncol"},{"key":"8072_CR10","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1245\/s10434-017-5930-3","volume":"24","author":"TT Nguyen","year":"2017","unstructured":"Nguyen TT, Hoskin TL, Day CN, Habermann EB, Goetz MP, Boughey JC (2017) Factors Influencing Use of Hormone Therapy for Ductal Carcinoma In Situ: A National Cancer Database Study. Ann Surg Oncol 24:2989\u20132998. https:\/\/doi.org\/10.1245\/s10434-017-5930-3","journal-title":"Ann Surg Oncol"},{"key":"8072_CR11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3747\/co.25.3795","volume":"25","author":"AT Chaudhry","year":"2018","unstructured":"Chaudhry AT, Koulis TA, Speers C, Olson RA (2018) Prescribing practices of endocrine therapy for ductal carcinoma in situ in British Columbia. Curr Oncol (Toronto Ont) 25:133\u2013138. https:\/\/doi.org\/10.3747\/co.25.3795","journal-title":"Curr Oncol (Toronto Ont)"},{"key":"8072_CR12","doi-asserted-by":"publisher","first-page":"113244","DOI":"10.1016\/j.ejca.2023.113244","volume":"192","author":"L van Walle","year":"2023","unstructured":"van Walle L, Verhoeven D, Marotti L, Ponti A, Tomatis M et al (2023) Trends and variation in treatment of early breast cancer in European certified breast centres: an EUSOMA-based analysis. Eur J Cancer 192:113244. https:\/\/doi.org\/10.1016\/j.ejca.2023.113244","journal-title":"Eur J Cancer"},{"key":"8072_CR13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.26698","author":"ES Hwang","year":"2024","unstructured":"Hwang ES, Hyslop T, Lynch T, Ryser MD, Weiss A et al (2024) Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial. JAMA. https:\/\/doi.org\/10.1001\/jama.2024.26698","journal-title":"JAMA"},{"key":"8072_CR14","unstructured":"(2009) New Zealand Guidelines Group. Management of early breast cancer. In, Wellington: New Zealand Guidelines Group"},{"key":"8072_CR15","unstructured":"(2022) Breast Cancer Foundation NZ. 30,000 voices: Informing a better future for breast cancer in Aotearoa New Zealand"},{"key":"8072_CR16","doi-asserted-by":"crossref","unstructured":"Ofri A, Tam SKM, Gill S, Spillane AJ (2025) Current pattern of care in radiation therapy for DCIS in Australia and New Zealand-where are we heading? The Breast 82:104482","DOI":"10.1016\/j.breast.2025.104482"},{"key":"8072_CR17","doi-asserted-by":"publisher","first-page":"e716","DOI":"10.1016\/S2214-109X(24)00521-7","volume":"13","author":"N Gobat","year":"2025","unstructured":"Gobat N, Slack C, Hannah S, Salzwedel J, Bladon G et al (2025) Better engagement, better evidence: working in partnership with patients, the public, and communities in clinical trials with involvement and good participatory practice. Lancet Glob Health 13:e716\u2013e731. https:\/\/doi.org\/10.1016\/S2214-109X(24)00521-7","journal-title":"Lancet Glob Health"},{"key":"8072_CR18","unstructured":"Pharmaceutical Collection. Health New Zealand | Te whatu ora. https:\/\/www.tewhatuora.govt.nz\/for-health-professionals\/data-and-statistics\/nz-health-statistics\/national-collections-and-surveys\/collections\/pharmaceutical-collection. Access ed 1 June 2025"},{"key":"8072_CR19","unstructured":"(2017) Ministry of Health, HISO 10001:2017 ethnicity data protocols"},{"key":"8072_CR20","volume-title":"NZDep2018 Index of Deprivation, Final Research Report, December 2020","author":"JSC Atkinson","year":"2019","unstructured":"Atkinson JSC, Crampton P (2019) NZDep2018 Index of Deprivation, Final Research Report, December 2020. University of Otago, Wellington"},{"key":"8072_CR21","unstructured":"Statistics New Zealand Datafinder: Urban Rural 2020 (generalised). https:\/\/datafinder.stats.govt.nz\/layer\/104269-urban-rural-2020-generalised\/. Accessed 2nd, November, 2025."},{"key":"8072_CR22","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","volume":"12","author":"E von Elm","year":"2014","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC et al (2014) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Int J Surg 12:1495\u20131499. https:\/\/doi.org\/10.1016\/j.ijsu.2014.07.013","journal-title":"Int J Surg"},{"key":"8072_CR23","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.radonc.2018.07.015","volume":"131","author":"I Meattini","year":"2019","unstructured":"Meattini I, Pasinetti N, Meduri B, De Rose F, De Santis MC et al (2019) A national multicenter study on 1072 DCIS patients treated with breast-conserving surgery and whole breast radiotherapy (COBCG-01 study). Radiother Oncol 131:208\u2013214. https:\/\/doi.org\/10.1016\/j.radonc.2018.07.015","journal-title":"Radiother Oncol"},{"key":"8072_CR24","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/sj.bjc.6604968","volume":"100","author":"B Cutuli","year":"2009","unstructured":"Cutuli B, Lemanski C, Fourquet A, de Lafontan B, Giard S et al (2009) Breast-conserving surgery with or without radiotherapy vs mastectomy for ductal carcinoma in situ: French Survey experience. Br J Cancer 100:1048\u20131054. https:\/\/doi.org\/10.1038\/sj.bjc.6604968","journal-title":"Br J Cancer"},{"key":"8072_CR25","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1055\/a-2505-1682","volume":"85","author":"S Burmeister","year":"2025","unstructured":"Burmeister S, Jozwiak K, Richter-Ehrenstein C, Buchali A, Holmberg C et al (2025) Treatment and Outcome of Ductal Carcinoma in Situ for the German Federal States Berlin and Brandenburg in the Period 2007\u20132020. Geburtshilfe Frauenheilkd 85:620\u2013630. https:\/\/doi.org\/10.1055\/a-2505-1682","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"8072_CR26","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1634\/theoncologist.2015-0310","volume":"21","author":"HB Nichols","year":"2016","unstructured":"Nichols HB, Bowles EJ, Islam J, Madziwa L, Sturmer T et al (2016) Tamoxifen Initiation After Ductal Carcinoma In Situ. Oncologist 21:134\u2013140. https:\/\/doi.org\/10.1634\/theoncologist.2015-0310","journal-title":"Oncologist"},{"key":"8072_CR27","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1200\/JCO.2010.34.0141","volume":"30","author":"DC Allred","year":"2012","unstructured":"Allred DC, Anderson SJ, Paik S, Wickerham DL, Nagtegaal ID et al (2012) Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol 30:1268\u20131273. https:\/\/doi.org\/10.1200\/JCO.2010.34.0141","journal-title":"J Clin Oncol"},{"key":"8072_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S1470-2045(10)70266-7","volume":"12","author":"J Cuzick","year":"2011","unstructured":"Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S et al (2011) Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK\/ANZ DCIS trial. Lancet Oncol 12:21\u201329. https:\/\/doi.org\/10.1016\/S1470-2045(10)70266-7","journal-title":"Lancet Oncol"},{"key":"8072_CR29","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/S0140-6736(15)01129-0","volume":"387","author":"JF Forbes","year":"2016","unstructured":"Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N et al (2016) Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Lancet 387:866\u2013873. https:\/\/doi.org\/10.1016\/S0140-6736(15)01129-0","journal-title":"Lancet"},{"key":"8072_CR30","unstructured":"Breast Cancer Research Trust. https:\/\/www.breastcancerresearch.org.nz\/breast-cancer-foundation-national-register\/. Accessed 8th, Feb, 2025"},{"key":"8072_CR31","doi-asserted-by":"publisher","first-page":"42045","DOI":"10.1038\/srep42045","volume":"7","author":"W Wang","year":"2017","unstructured":"Wang W, Zhu W, Du F, Luo Y, Xu B (2017) The Demographic Features, Clinicopathological Characteristics and Cancer-specific Outcomes for Patients with Microinvasive Breast Cancer: A SEER Database Analysis. Sci Rep 7:42045. https:\/\/doi.org\/10.1038\/srep42045","journal-title":"Sci Rep"},{"key":"8072_CR32","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12885-017-3797-0","volume":"18","author":"S Tin Tin","year":"2018","unstructured":"Tin Tin S, Elwood JM, Brown C, Sarfati D, Campbell I et al (2018) Ethnic disparities in breast cancer survival in New Zealand: which factors contribute? BMC Cancer 18:58. https:\/\/doi.org\/10.1186\/s12885-017-3797-0","journal-title":"BMC Cancer"},{"key":"8072_CR33","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.1245\/s10434-012-2413-4","volume":"19","author":"R Alvarado","year":"2012","unstructured":"Alvarado R, Lari SA, Roses RE, Smith BD, Yang W et al (2012) Biology, treatment, and outcome in very young and older women with DCIS. Ann Surg Oncol 19:3777\u20133784. https:\/\/doi.org\/10.1245\/s10434-012-2413-4","journal-title":"Ann Surg Oncol"},{"key":"8072_CR34","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s10549-024-07453-0","volume":"208","author":"EJA Bowles","year":"2024","unstructured":"Bowles EJA, Ramin C, Vo JB, Feigelson HS, Gander JC et al (2024) Endocrine therapy initiation among women diagnosed with ductal carcinoma in situ from 2001 to 2018. Breast Cancer Res Treat 208:577\u2013587. https:\/\/doi.org\/10.1007\/s10549-024-07453-0","journal-title":"Breast Cancer Res Treat"},{"key":"8072_CR35","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(15)01168-X","volume":"387","author":"RG Margolese","year":"2016","unstructured":"Margolese RG, Cecchini RS, Julian TB, Ganz PA, Costantino JP et al (2016) Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet 387:849\u2013856. https:\/\/doi.org\/10.1016\/S0140-6736(15)01168-X","journal-title":"Lancet"},{"key":"8072_CR36","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1200\/jco.22.02900","volume":"41","author":"M Lazzeroni","year":"2023","unstructured":"Lazzeroni M, Puntoni M, Guerrieri-Gonzaga A, Serrano D, Boni L et al (2023) Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study. J Clin oncology: official J Am Soc Clin Oncol 41:3116\u20133121. https:\/\/doi.org\/10.1200\/jco.22.02900","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"key":"8072_CR37","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/cncr.35009","volume":"130","author":"JM Mitchell","year":"2024","unstructured":"Mitchell JM, DeLeire T, Isaacs C (2024) Adherence to hormonal therapy after surgery among older women with ductal carcinoma in situ: Implications for breast cancer-related adverse health events. Cancer 130:107\u2013116. https:\/\/doi.org\/10.1002\/cncr.35009","journal-title":"Cancer"},{"key":"8072_CR38","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41523-025-00774-3","volume":"11","author":"TJ O\u2019Keefe","year":"2025","unstructured":"O\u2019Keefe TJ, Yau C, Iaconetti E, Jeong E, Brabham C et al (2025) Insights from a multi-institutional registry show duration of endocrine treatment for DCIS impacts second events. NPJ Breast Cancer 11:63. https:\/\/doi.org\/10.1038\/s41523-025-00774-3","journal-title":"NPJ Breast Cancer"},{"key":"8072_CR39","doi-asserted-by":"crossref","unstructured":"O\u2019Keefe T, Yau C, Lin S, Prionas N, Hirst GL et al (2025) Reframing hormone-positive DCIS management: Effects of adjuvant therapies and surgical extent on any invasive recurrence. Am Soc Clin Oncol","DOI":"10.1200\/JCO.2025.43.16_suppl.572"},{"key":"8072_CR40","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1200\/JCO.21.00831","volume":"39","author":"A Gupta","year":"2021","unstructured":"Gupta A, Jhawar SR, Sayan M, Yehia ZA, Haffty BG et al (2021) Cost-Effectiveness of Adjuvant Treatment for Ductal Carcinoma In Situ. J Clin Oncol 39:2386\u20132396. https:\/\/doi.org\/10.1200\/JCO.21.00831","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08072-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-08072-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08072-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:54:30Z","timestamp":1790312070000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-08072-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["8072"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-08072-7","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"18 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This is an observational study. Approval was granted the Auckland Health Research Ethics Committee (Ref. AH26746).","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"6"}}